PONTE
VEDRA, Fla., April 11,
2024 /PRNewswire/ -- Cadrenal Therapeutics,
Inc., (Nasdaq: CVKD), a biopharmaceutical company developing
tecarfarin, a late-stage novel oral and reversible anticoagulant
(blood thinner) designed to prevent heart attacks, strokes, and
deaths due to blood clots in patients with rare cardiovascular
conditions, will present at Noble Capital Markets' Emerging Growth
Virtual Healthcare Equity Conference on Thursday, April 18, 2024 at 1:00pm ET. The formal presentation will feature a
fireside style Q&A session with questions welcome from the live
virtual audience.
Attendees interested in viewing the live presentation can
register for this event, at no cost, here: Virtual Healthcare
Equity Conference Registration
Scheduled 1x1 meetings with our management are also available
for registered, qualified investor attendees. Please contact your
Noble Capital Markets representative or the Cadrenal's Investor
Relations team at CVKD@LythamPartners.com.
A video webcast of the presentation will be available following
the event on the Company's website at
https://www.cadrenal.com/investors/, and as part of a complete
catalog of presentations available at on Channelchek, the
investor portal created by Noble. The webcast will be archived on
the company's website and on Channelchek.com for 90 days following
the event.
ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal Therapeutics is developing tecarfarin for unmet needs
in anticoagulation therapy. Tecarfarin is a late-stage novel oral
and reversible anticoagulant (blood thinner) to prevent heart
attacks, strokes, and deaths due to blood clots in patients with
rare cardiovascular conditions. Tecarfarin has orphan drug and
fast-track designations from the FDA for the prevention of systemic
thromboembolism (blood clots) of cardiac origin in patients with
end-stage kidney disease (ESKD) and atrial fibrillation (AFib) and
just received orphan drug designation for the prevention of
thrombosis and thromboembolism in patients with ventricular assist
devices (VADs). Cadrenal is also pursuing additional regulatory
strategies for unmet needs in anticoagulation therapy for patients
with thrombotic antiphospholipid syndrome (APS). Tecarfarin is
specifically designed to leverage a different metabolism pathway
than the oldest and most commonly prescribed Vitamin K Antagonist
(warfarin). Tecarfarin has been evaluated in eleven (11) human
clinical trials and more than 1,000 individuals. In Phase 1, Phase
2, and Phase 2/3 clinical trials, tecarfarin has generally been
well-tolerated in both healthy adult subjects and patients with
chronic kidney disease.For more information, please visit:
www.cadrenal.com.
For more information, please contact:
Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
press@cadrenal.com
Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
CVKD@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cadrenal-therapeutics-to-participate-in-noble-capital-markets-emerging-growth-virtual-healthcare-equity-conference-on-april-18-2024-302114776.html
SOURCE Cadrenal Therapeutics, Inc.